ClinicalTrials.gg
Not yet recruitingNCT07469618Updated Mar 13, 2026

Efficacy of Cognitive Stimulation Therapy Integrated With Stress Reduction Intervention for Adults With Mild Cognitive Impairment

An interventional study of Cognitive Stimulation Therapy integrated with Stress Reduction Intervention and Cognitive Stimulation Therapy in Mild Cognitive Impairment (MCI), sponsored by University of the Punjab. Not yet recruiting. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by University of the Punjab · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Study summary

The aim of this study is to determine if integrating a culturally congruent indigenous stress reduction intervention into Cognitive Stimulation Therapy (CST) enhances cognitive outcomes in Pakistani adults with Mild Cognitive Impairment (MCI).

Read the detailed description

Mild Cognitive Impairment (MCI) is characterized by noticeable decline in cognitive functioning that is greater than expected for normal aging but does not significantly interfere with daily functioning. Cognitive Stimulation Therapy (CST) has been shown to improve cognitive functioning through structured activities that stimulate memory, attention, and problem-solving abilities. However, psychological stress is an important factor that may contribute to cognitive decline and reduced engagement in cognitive activities. The present randomized controlled trial aims to evaluate whether integrating a culturally congruent indigenous stress reduction intervention with CST enhances cognitive outcomes and reduces perceived stress among Pakistani adults with MCI. Participants will be randomly assigned to one of three groups: (1) CST integrated with a CBT-based stress reduction intervention, (2) CST only, and (3) a no-intervention control group. The interventions will be delivered over a period of seven weeks. Cognitive functioning will be assessed using the Montreal Cognitive Assessment (MoCA), and perceived stress will be assessed using the Perceived Stress Scale (PSS). Assessments will be conducted at baseline and after completion of the intervention period. The study aims to determine whether the integrated intervention provides greater benefits in improving cognitive functioning as compared to CST alone.

02

Conditions studied

  • Mild Cognitive Impairment (MCI)
03

In context

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

This study's planned enrollment of 12 is below the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.

Browse Cognitive Dysfunction studies →

Lead sponsor

University of the Punjab is the lead sponsor of 20 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 45 years and above
  • Individuals with education up to Matric
  • Individuals who obtain a score lower than 23 on (MoCA) suggesting the presence of cognitive decline.
  • Individuals who obtain a score of 14 or more on the Perceived Stress Scale suggesting increased levels of perceived stress (moderate and high)
  • Individuals who obtain score ranged from 13 to 25 (Poor to Adequate) on Quality of Life in Alzheimer's Disease (Qol-AD)

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of dementia or major neurocognitive disorder
  • Presence of severe psychiatric illness (e.g., psychosis, major depressive episode)
  • Significant hearing or visual impairments that interfere with participation
  • Currently undergoing psychological or cognitive therapy
  • Any neurological condition that may interfere with cognitive assessment (e.g., stroke, Parkinson's disease)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Cognitive Stimulation Therapy integrated with Stress Reduction Intervention

    Participants receive Cognitive Stimulation Therapy integrated with Stress Reduction Intervention for 7 weeks.

    Behavioral: Cognitive Stimulation Therapy integrated with Stress Reduction Intervention

  • Active comparator
    Cognitive Stimulation Therapy (CST)

    Participants receive Cognitive Stimulation Therapy sessions for 7 weeks.

    Behavioral: Cognitive Stimulation Therapy

  • No intervention
    Control Group

    Participants will not receive any structured therapy during the 7 week study period.

Interventions

  • BehavioralCognitive Stimulation Therapy integrated with Stress Reduction Intervention

    Participants in this Arm will receive Cognitive Stimulation Therapy integrated with Stress Reduction Intervention for 7 weeks, combining structured cognitive exercises targeting memory, attention, and problem-solving with guided stress reduction techniques.

  • BehavioralCognitive Stimulation Therapy

    Participants in this Arm will attend Cognitive Stimulation Therapy sessions only for 7 weeks, including structured cognitive exercises targeting memory, attention, and problem-solving in a group format.

06

What researchers measure

Primary outcomes

  1. Change in Montreal Cognitive Assessment (MoCA) total score from baseline to 7 weeks

    The Montreal Cognitive Assessment (MoCA) will be used to assess overall cognitive functioning, including attention, memory, language, executive functions, and visuospatial abilities. The MoCA total score ranges from 0 to 30, with higher scores indicating better cognitive functioning. Assessments will be conducted at baseline and after completion of the 7-week intervention period.

    Time frame: 7 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Jun 2026, 3 months later.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 3 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2026
First posted
Mar 13, 2026
StartEst.
Mar 2026
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2026
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07469618
Lead sponsor
University of the Punjab
Responsible party
Saliha Moazzam (Student, University of the Punjab) — Principal investigator
First posted
Mar 13, 2026
Start date
Mar 2026 (estimated)
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Mar 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion